Skip to main content
. 2017 Apr 13;8(32):52678–52689. doi: 10.18632/oncotarget.17079

Figure 1. In vivo expansion of Foxp3+ Tregs with IL-2/JES6-1 complex in rel−/− mice.

Figure 1

(A) CD4+ T cells purified from wild-type (WT) and rel−/− mice were stimulated with anti-CD3 plus anti-CD28 for 24h. IL-2 secretion was measured by ELISA. Data are means ± SEM; ***P<0.001. (B) WT and rel−/− mice were treated i.p. daily for three days (days 0, 1, 2) with IL-2/JES6-1. The expansion of Tregs was analyzed on day 5 by the intracellular staining of Foxp3 in mLN and spleen. The histograms are gated on CD4+ T cells. Data are representative of two independent experiments. (C) and (D) The percentage (C) and total cell number (D) of Tregs in mLN and spleen on day 5 after treatment of mice with IL-2/JES6-1 (n = 6 mice per group). Results are means ± SEM; *P<0.05, **P<0.01, ***P<0.001. (E) A kinetic analysis of Treg expansion after IL-2/JES6-1 treatment of WT and rel−/− mice. Foxp3 frequencies among CD4+ T cells on days 0, 5, 8 and 15 following three injections of IL-2/ JES6-1 are shown (n = 6 per group). Error bars represent SEM.